2026-04-17T20:25:13Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/128842025-05-03T03:20:03Zcom_2072_378070com_2072_378040col_2072_378092

00925njm 22002777a 4500 dc Sobrero, Alberto author Dasari, Arvind author Jeneth Aquino, Jeneth Aquino author Elez, Elena author Lonardi, Sara author Garcia-Carbonero, Rocio author Tabernero, Josep author 2025-04-02T12:40:35Z 2025-04-02T12:40:35Z 2025-03-11 Fruquintinib; Health-related quality of life; Metastatic colorectal cancer Fruquintinib; Calidad de vida relacionada con la salud; Cáncer colorrectal metastásico Fruquintinib; qualitat de vida relacionada amb la salut; Càncer colorectal metastàtic Introduction Maintaining or improving health-related quality of life (HRQoL) is as important as extending survival in metastatic colorectal cancer. We report an HRQoL analysis from FRESCO-2 (NCT04322539). Methods Patients were randomized to fruquintinib +best supportive care (BSC; n = 461) or placebo +BSC (n = 230). Instruments of EORTC QLQ-C30 and 5-level EQ-5D, and ECOG performance status (PS) were assessed. Changes from baseline scores for QLQ-C30 and EQ-5D were evaluated and minimally important difference thresholds were used to define stable, improved, or deteriorated QoL. Time to deterioration (TTD) was assessed. Results With fruquintinib versus placebo, baseline QLQ-C30 global health status (GHS) and EQ-5D visual analog scale (VAS) scores were 65.2 versus 64.6 and 67.0 versus 66.6, respectively. Least-squares mean changes from baseline fluctuated throughout treatment. At end of treatment (EOT), mean scores with fruquintinib versus placebo were 53.8 versus 52.3 (QLQ-C30 GHS) and 58.9 versus 58.5 (EQ-5D VAS). For QLQ-C30 GHS, 38.3 % versus 36.5 % of patients receiving fruquintinib versus placebo had stable or improved scores at EOT; median TTD was 2.1 versus 1.8 months (HR, 0.9; 95 % CI, 0.7–1.0). For EQ-5D VAS, 47.9 % versus 42.7 % had stable or improved scores at EOT; median TTD was 2.6 versus 1.9 months (HR, 0.8; 95 % CI, 0.6–0.9). Median TTD to ECOG PS ≥ 2 or death within 30+ /7 days after EOT was 6.6 versus 2.9 months with fruquintinib versus placebo (HR, 0.6; 95 % CI, 0.4–0.7). Conclusions Fruquintinib delayed TTD of ECOG PS and did not negatively impact HRQoL versus placebo. This study was funded by HUTCHMED. http://hdl.handle.net/11351/12884 Còlon - Càncer - Tractament Recte - Càncer - Tractament Metàstasi Pacients - Satisfacció Proteïnes quinases - Inhibidors - Ús terapèutic CHEMICALS AND DRUGS::Enzymes and Coenzymes::Enzymes::Transferases::Phosphotransferases::Phosphotransferases (Alcohol Group Acceptor)::Protein Kinases::Protein-Tyrosine Kinases Other subheadings::Other subheadings::Other subheadings::/antagonists & inhibitors HEALTH CARE::Environment and Public Health::Public Health::Epidemiologic Measurements::Demography::Health Status::Quality of Life DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms Other subheadings::Other subheadings::Other subheadings::/drug therapy COMPUESTOS QUÍMICOS Y DROGAS::enzimas y coenzimas::enzimas::transferasas::fosfotransferasas::fosfotransferasas (grupo alcohol aceptor)::proteína cinasas::proteína-tirosina cinasas Otros calificadores::Otros calificadores::Otros calificadores::/antagonistas & inhibidores ATENCIÓN DE SALUD::ambiente y salud pública::salud pública::medidas epidemiológicas::demografía::estado de salud::calidad de vida ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia Health-related quality of life associated with fruquintinib in patients with metastatic colorectal cancer: Results from the FRESCO-2 study